# Jasper Therapeutics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Jasper Therapeutics, Inc.). ## Overview Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on mast cell therapeutics, with briquilimab as its core asset. The company is working to develop and commercialize treatments for chronic urticaria and other mast-cell-related indications, while also retaining rights to use briquilimab in stem cell clearance prior to hematopoietic stem cell transplantation. ## Products & services • Briquilimab monoclonal antibody for mast cell therapeutics • Briquilimab development in chronic urticaria • Briquilimab use in stem cell clearance before transplant • Preclinical and clinical development programs • Regulatory approval and future commercialization efforts - **Lead biologic candidate** (100%) — Briquilimab, the company's main monoclonal antibody program, developed for mast cell-related diseases. - **Clinical development programs** (0%) — Research, preclinical work, and clinical trials supporting briquilimab and related indications. - **Licensing rights** (0%) — Exclusive rights licensed from Amgen and Stanford University for specific uses of briquilimab. - Briquilimab monoclonal antibody - Chronic urticaria clinical development - Stem cell clearance prior to transplant - Preclinical and clinical development programs - Regulatory approval and commercialization planning ## Customers Jasper does not yet sell commercial products; its near-term 'customers' are clinical trial participants, investigators, regulators, and future payers that will determine whether briquilimab can be approved and reimbursed. If approved, the company expects to commercialize in North America directly and may use partners outside North America, so future buyers would include physicians, hospitals, and specialty payers in the relevant disease areas. - **Clinical trial participants** (primary) — Patients enrolled in briquilimab studies, especially chronic urticaria, to generate efficacy and safety data. - **Regulators** (primary) — FDA and foreign agencies that review clinical packages and determine whether the drug can be approved. - **Future specialty prescribers** (secondary) — Allergists, immunologists, and transplant-related clinicians who would prescribe briquilimab if approved. - **Payers** (secondary) — Commercial and government payers that will decide coverage and reimbursement for launch. - Clinical trial investigators and sites running briquilimab studies - Patients with chronic urticaria and other mast-cell disorders - Regulators such as the FDA reviewing safety and efficacy data - Payers and reimbursement bodies that will shape launch access - Future physicians and hospitals if briquilimab reaches market ## Geography Jasper is headquartered in the United States and currently operates as a development-stage biotech with no commercial sales infrastructure. Management has said it may build commercialization capabilities in North America first, while outside North America it may rely on licensing, co-sale, or co-promotion partners. That makes the U.S. the key operating base and North America the likely initial launch region if briquilimab is approved. - Headquartered in the United States - Primary operating base for R&D and corporate functions - North America is the planned first commercialization region - Outside North America, commercialization may be partner-led - No disclosed country revenue because there are no product sales ## Strategy The company has narrowed its focus to briquilimab and chronic urticaria after halting enrollment in its asthma study and stopping other clinical and preclinical programs. Its strategy is to conserve capital, advance the most promising indication, and preserve optionality through licensing and strategic alliances while it seeks additional financing. Jasper also intends to broaden its pipeline over time with additional mast-cell indications and next-generation products if resources allow. - **Advance briquilimab in chronic urticaria** (short-term) — This is the company's highest-priority asset and the main path to value creation and eventual revenue. - **Preserve cash and raise capital** (short-term) — The company expects continued losses and needs external funding to keep development programs running. - **Prepare for commercialization** (medium-term) — If approved, Jasper will need sales, marketing, manufacturing, and distribution capabilities to launch briquilimab. - Focus resources on briquilimab and chronic urticaria - Stop lower-priority programs to extend cash runway - Advance through clinical development and regulatory review - Build North America launch capability if approved - Use partnerships outside North America where efficient ## Risks Jasper is a pre-revenue biotech with significant accumulated losses, negative operating cash flow, and a continuing need for external capital. Its value depends heavily on clinical success, regulatory approval, and eventual reimbursement for briquilimab, while any setback in development, manufacturing, or funding could materially impair the business. The company also faces typical biotech risks around trial design, patient enrollment, IP protection, and changing FDA expectations. - **Clinical development failure** [critical] — Briquilimab must show adequate safety and efficacy in trials before approval and commercialization are possible. - **Financing risk** [high] — The company expects continued losses and may need to curtail programs if capital is unavailable. - **Regulatory risk** [high] — FDA requirements may change or additional studies may be required, delaying approval. - **Commercialization and reimbursement risk** [high] — Even with approval, the company must secure pricing and payer coverage to generate meaningful sales. - **IP and licensing dependence** [high] — The business relies on exclusive licenses for briquilimab rights and must maintain those agreements. - No commercial revenue until a product is approved - High dependence on briquilimab clinical and regulatory success - Ongoing need for external capital and dilution risk - Trial delays, failures, or safety issues could halt development - Reimbursement and pricing uncertainty could limit launch economics ## Accounting The most important accounting issue is that Jasper is pre-commercial, so reported results are dominated by R&D expense, stock-based compensation, and cash burn rather than product revenue. Investors should also watch estimates tied to clinical and manufacturing accruals, lease costs, and any fair-value accounting for warrants or financing instruments, because these can move reported expenses and equity values materially. As a development-stage company, impairment and valuation judgments around intangible rights and capitalized assets can also become important if programs are discontinued. - **Research and development accruals** — Can shift quarterly operating expense and liabilities - **Stock-based compensation** — Raises non-cash operating expense and affects loss metrics - **Warrant fair value** — Can create volatility in other income/expense and equity - **Impairment and write-offs** — May cause one-time charges if projects are abandoned - No product revenue yet, so results are driven by R&D spending - Clinical trial and manufacturing accrual estimates affect expense timing - Stock-based compensation is a meaningful non-cash expense - Warrant and financing instrument valuation can affect equity and earnings - Program discontinuations may trigger asset impairment or write-offs --- *Last updated: 2026-04-28T20:18:59.173101+00:00*